gastric or gastro-oesophageal junction cancer (advanced)

systematic review meta-analysis network meta-analysis

Select immune checkpoint inhibition All type of patient       anti PD-1 nivolumabpembrolizumab       2nd linePD-L1 positive

Filter

Group by Group by... nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition MA  in first nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in second nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in third	Description Synopsis Comparison Treatments Patients Characteristics Method Risk of bias References None Tools Indexation					Results Global trial result Main results All results All result tag NCT results	death (overall survival) (2)progression or death (progression free survival PFS) (1) Options Numeric bar chart forest plot medians
Trial	Studied trt	Control trt	patients	tags	ROB	Trial result	death (overall survival)	progression or death (progression free survival PFS)
immune checkpoint inhibition
nivolumab
ATTRACTION-2, 2017      NCT	nivolumab	placebo			Low risk of bias	suggesting
pembrolizumab
KEYNOTE-059 single-arm      NCT	pembrolizumab	nil				-
Keynote 061, 2018    NCT	pembrolizumab	paclitaxel	2L	2nd line PD-L1 positive	Risk of bias	negative